Daily Archives: April 12, 2018

FDA Enforcement Lags, Focus on Promotion of Unapproved Drugs

It goes without saying that enforcement by FDA’s Office of Prescription Drug Promotion (OPDP) as identified through regulatory action letters (warning or untitled) over the past few years is a mere shadow of its former self. Enforcement was once robust, … Continue reading

Posted in FDA Policy | Comments Off on FDA Enforcement Lags, Focus on Promotion of Unapproved Drugs